Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: INT054
MIFTS: 50

Intraocular Lymphoma

Categories: Eye diseases, Blood diseases, Rare diseases, Neuronal diseases, Cancer diseases, Immune diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Intraocular Lymphoma

About this section

MalaCards integrated aliases for Intraocular Lymphoma:

Name: Intraocular Lymphoma 38 12 76 55 44 15 73
Primary Intraocular Lymphoma 12 59
Primary Intraocular Non-Hodgkin Malignant Lymphoma 73
Primary Intraocular Non-Hodgkin's Lymphoma 59
Piol 59

Characteristics:

Orphanet epidemiological data:

59
primary intraocular lymphoma
Inheritance: Not applicable; Age of onset: Adult; Age of death: elderly;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Eye diseases Blood diseases Neuronal diseases Immune diseases
See all MalaCards categories (disease lists)
Orphanet: 59  
Rare eye diseases
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:775
MeSH 44 D064090
NCIt 50 C9184
Orphanet 59 ORPHA279904
UMLS via Orphanet 74 C0281658
ICD10 via Orphanet 34 C85,7
Sources

Summaries for Intraocular Lymphoma

About this section
MalaCards based summary : Intraocular Lymphoma, also known as primary intraocular lymphoma, is related to lymphoma and central nervous system lymphoma. An important gene associated with Intraocular Lymphoma is IL10 (Interleukin 10), and among its related pathways/superpathways are Akt Signaling and PAK Pathway. The drugs Ketamine and Amoxicillin have been mentioned in the context of this disorder. Affiliated tissues include b cells, brain and eye, and related phenotypes are cellular and hematopoietic system

Wikipedia : 76 Intraocular lymphoma is a rare malignant form of eye cancer. Intraocular lymphoma may affect the eye... more...

Sources

Related Diseases for Intraocular Lymphoma

About this section

Diseases related to Intraocular Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Related Disease Score Top Affiliating Genes
1 lymphoma 30.2 BCL6 CXCR5 PAX5
2 central nervous system lymphoma 28.7 BCL6 CXCL12 IL10
3 primary central nervous system lymphoma 28.5 BCL6 CXCL12 PAX5
4 acquired immunodeficiency syndrome 28.4 BCL6 IL10
5 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 10.3 BCL6 CXCR5
6 neurosyphilis 10.2 CXCR5 IL10
7 eye lymphoma 10.2 C19orf48 IL10
8 waldenstrom macroglobulinemia 10.1 CXCR4 PAX5
9 retinitis 10.1
10 mitral valve disease 10.0 CXCR4 IL10
11 nodular lymphocyte predominant hodgkin lymphoma 10.0 BCL6 PAX5
12 composite lymphoma 10.0 BCL6 PAX5
13 mediastinal malignant lymphoma 9.9 BCL6 PAX5
14 aids dementia complex 9.9 CXCL12 CXCR4
15 lung lymphoma 9.9 BCL6 PAX5
16 whim syndrome 9.9 CXCL12 CXCR4
17 uveitis 9.9
18 chorioretinitis 9.9
19 retinal hemangioblastoma 9.8 CXCL12 CXCR4
20 splenic marginal zone lymphoma 9.8 BCL6 PAX5
21 reticulosarcoma 9.8 BCL6 PAX5
22 cytomegalovirus retinitis 9.8
23 choroiditis 9.8
24 panuveitis 9.8
25 lymphoma, mucosa-associated lymphoid type 9.7 BCL6 CXCR5
26 leukemia, acute lymphoblastic 3 9.7 CXCR5 PAX5
27 lymphoma, hodgkin, classic 9.7 BCL6 PAX5
28 systemic lupus erythematosus 9.6
29 rheumatoid arthritis 9.6
30 temporal arteritis 9.6
31 reticulum cell sarcoma 9.6
32 arthritis 9.6
33 testicular lymphoma 9.6
34 hypopyon 9.6
35 sarcoma 9.6
36 retinal vasculitis 9.6
37 cerebritis 9.6
38 endophthalmitis 9.6
39 cerebral lymphoma 9.6
40 breast lymphoma 9.6
41 retina lymphoma 9.6
42 vasculitis 9.6
43 lupus erythematosus 9.6
44 iridocyclitis 9.6
45 meningitis 9.6
46 orbit lymphoma 9.6
47 multifocal choroiditis 9.6
48 orbital lymphoma 9.6
49 lymphomatous meningitis 9.6
50 polyradiculoneuropathy 9.6 CXCL12 IL10

Graphical network of the top 20 diseases related to Intraocular Lymphoma:



Diseases related to Intraocular Lymphoma
Sources

Symptoms & Phenotypes for Intraocular Lymphoma

About this section

MGI Mouse Phenotypes related to Intraocular Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.73 IL10 PAX5 BCL6 CXCL12 CXCR4 CXCR5
2 hematopoietic system MP:0005397 9.63 PAX5 BCL6 CXCL12 CXCR4 CXCR5 IL10
3 immune system MP:0005387 9.43 IL10 PAX5 BCL6 CXCL12 CXCR4 CXCR5
4 normal MP:0002873 9.02 IL10 PAX5 BCL6 CXCL12 CXCR5
Sources

Drugs & Therapeutics for Intraocular Lymphoma

About this section

Drugs for Intraocular Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 258)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Amoxicillin Approved, Vet_approved Phase 3,Not Applicable 26787-78-0 33613
3
Ciprofloxacin Approved, Investigational Phase 3,Not Applicable 85721-33-1 2764
4
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
5
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
6
Ofloxacin Approved Phase 3 82419-36-1 4583
7
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
8
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
9
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
10
Melphalan Approved Phase 2, Phase 3,Phase 1,Not Applicable 148-82-3 4053 460612
11
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 52-24-4 5453
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
13
Ondansetron Approved Phase 3,Not Applicable 99614-02-5 4595
14
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
15
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
16
Busulfan Approved, Investigational Phase 2, Phase 3,Early Phase 1,Not Applicable 55-98-1 2478
17
Carboplatin Approved Phase 2, Phase 3,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
18
Etoposide Approved Phase 2, Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
19 Orange Approved, Nutraceutical Phase 3
20
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
21
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
22 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
23 Analgesics Phase 3,Phase 1,Not Applicable
24 Anesthetics Phase 3
25 Anesthetics, Dissociative Phase 3
26 Anesthetics, General Phase 3
27 Anesthetics, Intravenous Phase 3
28 Central Nervous System Depressants Phase 3,Phase 1,Phase 2,Not Applicable
29 Excitatory Amino Acid Antagonists Phase 3,Phase 1
30 Excitatory Amino Acids Phase 3,Phase 1
31 Neurotransmitter Agents Phase 3,Phase 1,Not Applicable
32 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Amoxicillin-Potassium Clavulanate Combination Phase 3,Not Applicable
34 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
35 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
36 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
37 Antitubercular Agents Phase 3,Phase 2,Phase 1,Not Applicable
38 beta-Lactamase Inhibitors Phase 3,Not Applicable
39 Clavulanic Acid Phase 3,Not Applicable
40 Cytochrome P-450 CYP1A2 Inhibitors Phase 3,Not Applicable
41 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
42 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
43 Cephalosporins Phase 3
44 Renal Agents Phase 3,Phase 1,Phase 2
45 Liver Extracts Phase 3,Phase 1,Not Applicable
46 Hormones Phase 3,Phase 2,Phase 1
47 Antiemetics Phase 3,Phase 2,Phase 1,Not Applicable
48 Autonomic Agents Phase 3,Phase 2,Phase 1,Not Applicable
49 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 154)
# Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
3 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
4 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
5 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
6 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
9 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
10 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
11 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
12 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
13 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
14 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
15 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
16 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
17 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
18 Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma Completed NCT00074191 Phase 2 cytarabine;dexamethasone;lomustine;methotrexate;procarbazine hydrochloride
19 Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma Completed NCT00074178 Phase 2 cyclophosphamide;cytarabine;dexamethasone;etoposide phosphate;methotrexate
20 Radiation Therapy and High-Dose Corticosteroids in Treating Older Patients With Primary CNS Non-Hodgkin's Lymphoma Completed NCT00003278 Phase 2 dexamethasone
21 A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae Completed NCT01010295 Phase 2 doxycycline (tetracycline)
22 High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma Completed NCT01182415 Phase 2 High-dose chemotherapy
23 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
24 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
25 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
26 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
27 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
28 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
29 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
30 Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma Completed NCT00054639 Phase 2
31 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Completed NCT00867529 Phase 2
32 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
33 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
34 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
35 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
36 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
37 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
38 Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Completed NCT00002502 Phase 2 busulfan;cyclophosphamide;cytarabine
39 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
40 Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy Completed NCT00066599 Phase 2 voriconazole
41 Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer Completed NCT00006225 Phase 1, Phase 2
42 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas Recruiting NCT02213913 Phase 1, Phase 2 lenalidomide;etoposide;prednisone;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide
43 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
44 Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Recruiting NCT01643603 Phase 1, Phase 2 Dasatinib
45 Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Recruiting NCT01609816 Phase 1, Phase 2 Dasatinib
46 Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma Active, not recruiting NCT02542514 Phase 2 Ibrutinib
47 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01839916 Phase 2
48 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Active, not recruiting NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
49 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
50 A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma. Terminated NCT00517699 Phase 2 rituximab [MabThera/Rituxan];Methotrexate;Cytarabine

Search NIH Clinical Center for Intraocular Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Intraocular Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Intraocular Lymphoma:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Intraocular Lymphoma:
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: intraocular lymphoma

Sources

Genetic Tests for Intraocular Lymphoma

About this section
Sources

Anatomical Context for Intraocular Lymphoma

About this section

MalaCards organs/tissues related to Intraocular Lymphoma:

41
B Cells, Brain, Eye, Bone, Bone Marrow, Retina, Liver
Sources

Publications for Intraocular Lymphoma

About this section

Articles related to Intraocular Lymphoma:

(show top 50) (show all 205)
# Title Authors Year
1
Interleukins in the Diagnosis of Intraocular Lymphoma: Do We Still Need Histologic Confirmation? ( 29561391 )
2018
2
Highly suspected primary intraocular lymphoma in a patient with rheumatoid arthritis treated with etanercept: a case report. ( 29954352 )
2018
3
Metagenomic deep sequencing of aqueous fluid detects intraocular lymphomas. ( 29122821 )
2018
4
Clinical and pathological classification of canine intraocular lymphoma. ( 28714087 )
2017
5
Orbital and Intraocular Lymphoma in Contralateral Eyes: A Case of Cutaneous Aggressive CD-8+ T-Cell Lymphoma. ( 28433127 )
2017
6
Retinal necrosis as the initial presentation of primary intraocular lymphoma. ( 29022962 )
2017
7
Clinical features and outcomes of secondary intraocular lymphoma. ( 29143310 )
2017
8
THERAPEUTIC VITRECTOMY AS AN ADJUNCT TREATMENT TO SYSTEMIC CHEMOTHERAPY FOR INTRAOCULAR LYMPHOMA. ( 29210961 )
2017
9
Intraocular Lymphoma Masquerading as Recurrent Iridocyclitis: Findings Based on in vivo Confocal Microscopy. ( 29099641 )
2017
10
Intraocular lymphoma. ( 28861359 )
2017
11
Combined intravitreal methotrexate and immunochemotherapy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B-cell primary intraocular lymphoma. ( 28699673 )
2017
12
Cytopathologic findings of cell block materials from the vitreous: Diagnostic distinction between intraocular lymphoma and non-lymphomatous diseases. ( 28590047 )
2017
13
Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection. ( 26732884 )
2016
14
ISOLD: A New Highly Sensitive Interleukin Score for Intraocular Lymphoma Diagnosis. ( 26948307 )
2016
15
Atypical presentation of primary intraocular lymphoma. ( 27716122 )
2016
16
Transient therapeutic effect of vitrectomy in primary intraocular lymphoma. ( 27904987 )
2016
17
High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma. ( 27412324 )
2016
18
Intraocular Lymphoma: Descriptive Data of 26 Patients Including Clinico-pathologic Features, Vitreous Findings, and Treatment Outcomes. ( 27438792 )
2016
19
Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma. ( 27075636 )
2016
20
[Radiotherapy of primary intraocular lymphoma associated with primary central nervous system lymphoma]. ( 27296540 )
2016
21
Therapeutic vitrectomy for vitreal recurrence of intraocular lymphoma resistant to intravitreal methotrexate post systemic chemotherapy. ( 26458712 )
2015
22
Spectral-domain Optical Coherence Tomography Patterns in Intraocular Lymphoma. ( 25760916 )
2015
23
Changes of choroidal structure after treatment for primary intraocular lymphoma: retrospective, observational case series. ( 26482033 )
2015
24
Intraocular Lymphoma Models. ( 27171354 )
2015
25
The Role of Chorioretinal Biopsy in the Diagnosis of Intraocular Lymphoma. ( 26344582 )
2015
26
Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study. ( 26770952 )
2015
27
Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. ( 26487691 )
2015
28
Case of Primary Intraocular Lymphoma with Extraocular Extension. ( 27171820 )
2015
29
Cytologic features in vitreous preparations of patients with suspicion of intraocular lymphoma. ( 24167062 )
2014
30
Primary intraocular lymphoma. ( 24560125 )
2014
31
Fundus autofluorescence patterns in primary intraocular lymphoma. ( 23958842 )
2014
32
Spectral-domain optical coherence tomographic and fundus autofluorescence findings in eyes with primary intraocular lymphoma. ( 24520190 )
2014
33
Changes of fundus autofluorescence and spectral-domain optical coherence tomographic findings after treatment of primary intraocular lymphoma. ( 24559259 )
2014
34
Improving the cytological diagnosis of intraocular lymphoma from vitreous fluid. ( 25413989 )
2014
35
25-gauge transconjunctival diagnostic vitrectomy in suspected cases of intraocular lymphoma: a case series and review of the literature. ( 24967211 )
2014
36
Survival Outcomes of Primary Intraocular Lymphoma: A Single-institution Experience. ( 24390272 )
2014
37
The trabectome as treatment option in secondary glaucoma due to intraocular lymphoma. ( 25170980 )
2014
38
Diagnostic vitrectomy for primary intraocular lymphoma: when, why, how? ( 24613891 )
2014
39
High-resolution genomic copy number profiling of primary intraocular lymphoma by single nucleotide polymorphism microarrays. ( 24612100 )
2014
40
Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma. ( 23449111 )
2013
41
Intraocular lymphoma after cardiac transplantation: magnetic resonance imaging findings. ( 23323042 )
2013
42
Cytokine profile in human eyes: contribution of a new cytokine combination for differential diagnosis between intraocular lymphoma or uveitis. ( 23405064 )
2013
43
Development of Chitosan and Poly-Lactic Acid (PLA) based Methotrexate (MTX) intravitreal micro-implants to treat primary intraocular lymphoma: an in-vitro study. ( 24317155 )
2013
44
Unilateral retinopathy secondary to occult primary intraocular lymphoma. ( 24081663 )
2013
45
Secondary orbital and intraocular lymphoma treated with immunochemotherapy. ( 25391121 )
2013
46
A possible coincidence of cytomegalovirus retinitis and intraocular lymphoma in a patient with systemic non-Hodgkin's lymphoma. ( 23295015 )
2013
47
Intraocular lymphoma: a clinical perspective. ( 23196650 )
2013
48
Two cases of intraocular lymphoma diagnosed by analyses of vitreous and infusion fluid. ( 23589676 )
2013
49
Multicolor flowcytometric immunophenotyping is a valuable tool for detection of intraocular lymphoma. ( 23380473 )
2013
50
Primary intraocular lymphoma: treatment outcomes with ocular radiation therapy alone. ( 23822539 )
2013
Sources

Variations for Intraocular Lymphoma

About this section
Sources

Expression for Intraocular Lymphoma

About this section
Search GEO for disease gene expression data for Intraocular Lymphoma.
Sources

Pathways for Intraocular Lymphoma

About this section

Pathways related to Intraocular Lymphoma according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Akt Signaling 64
Show member pathways
 12.97 CXCL12 CXCR4 CXCR5 IL10
2
PAK Pathway 64
Show member pathways
 12.84 CXCL12 CXCR4 CXCR5 IL10
3
Allograft rejection 1 37
Show member pathways
 12.36 CXCL12 CXCR4 CXCR5 IL10
4
NF-kappaB Signaling 4
11.95 BCL6 CXCL12 CXCR4 CXCR5 IL10 PAX5
5
Innate Lymphoid Cell Differentiation Pathways 65
11.41 CXCR5 IL10
6
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 65
Show member pathways
 11.4 CXCL12 CXCR4 CXCR5
7
CXCR4-mediated signaling events 1
11.38 CXCL12 CXCR4
8
Jak-Stat Signaling Pathway 67
11.38 CXCL12 CXCR4 IL10
9
HIF-1-alpha transcription factor network 1
11.27 CXCL12 CXCR4
10
IL4-mediated signaling events 1
11.23 BCL6 IL10
11
Signaling by Slit 64
11.09 CXCL12 CXCR4
12
Syndecan-4-mediated signaling events 1
10.86 CXCL12 CXCR4
13
B Cell Development Pathways 65
10.75 BCL6 CXCR4 CXCR5 IL10 PAX5
Sources

GO Terms for Intraocular Lymphoma

About this section

Biological processes related to Intraocular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.63 CXCL12 CXCR5 IL10
2 inflammatory response GO:0006954 9.5 BCL6 CXCR4 IL10
3 positive regulation of neuron differentiation GO:0045666 9.43 BCL6 CXCL12
4 chemotaxis GO:0006935 9.43 CXCL12 CXCR4 CXCR5
5 B cell differentiation GO:0030183 9.4 BCL6 IL10
6 positive regulation of endothelial cell proliferation GO:0001938 9.37 CXCL12 IL10
7 leukocyte chemotaxis GO:0030595 9.16 CXCR5 IL10
8 type 2 immune response GO:0042092 8.96 BCL6 IL10
9 chemokine-mediated signaling pathway GO:0070098 8.8 CXCL12 CXCR4 CXCR5

Molecular functions related to Intraocular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 C-X-C chemokine receptor activity GO:0016494 8.62 CXCR4 CXCR5
Sources

Sources for Intraocular Lymphoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....